Key points are not available for this paper at this time.
Design
Editorial
Answers are grounded in this paper and cite their sources.
This editorial highlights the potential of pulse pressure as an early predictor of kidney disease progression but emphasizes the need for larger studies to confirm its independent predictive value over systolic blood pressure.
Brachial artery pulse pressure (BPP) is a well studied clinical parameter that provides mixed results as a cardiovascular prognosticator. This is exemplified by the results of the Prospective Studies Collaborative Group meta-analysis that reported no correlation between cardiovascular events and BPP in one million patients [1]. Conversely, the Framingham Study concluded that BPP was the best predictor of cardiovascular diseases in individuals more than 60 years of age [2]. The Medical Research Council Mild Hypertension Trial also demonstrated that BPP was a stronger predictor of coronary events than systolic, diastolic or mean blood pressure, whereas mean blood pressure predicted future cerebrovascular events [3]. In 24-h ambulatory blood pressure monitoring studies, the incidence of coronary events was related directly to increases in BPP. Verdecchia and colleagues [4] reported that for each 10 mmHg increase in 24-h BPP, a 35% higher risk of cardiac events was present. It has now been 6–7 years since the aforementioned publications, more recent studies, however, have identified changes in central aortic pressure as a relatively stronger predictor of cardiovascular outcomes compared with BPP. Moreover, changes in central aortic pressure differ from changes in peripheral BPP. This observation was apparent in a study of 4000 normal individuals whose brachial cuff pressures were as high as 1.7 times that of the aortic pressure. This was in contrast to middle-aged and elderly individuals whose brachial cuff pressures were only 1.2 times greater than aortic pressures. These differences have also to be put into context given the large standard deviation of the measurement for all ages [5]. As a result of these and other studies more attention has been paid towards modalities that measure central pulse wave dynamics [6]. Although differences in central pressure are better at explaining cardiovascular outcomes compared with peripheral pressures, as exemplified in the CAFÉ study [7], the implications for kidney disease outcomes is less well defined. A sub-study of the RENAAL trial demonstrated that the administration of losartan (in comparison with placebo) in patients with a baseline pulse pressure above 90 mmHg had a 53.5% risk reduction for end-stage renal disease alone and a 35.5% risk reduction for end-stage renal disease or death [8]. In three separate studies of hemodialysis patients, pulse pressure independently predicted increases in mortality [9–11]. In contrast, the Irbesartan Diabetic Nephropathy Trial demonstrated that baseline as well as achieved systolic blood pressure were the main determinants of renal outcome, with no further improvement in predictive power when pulse pressure was included in the multivariate model [12]. In the current issue, Fesler et al.[13] examined pulse pressure as a predictor of progressive renal dysfunction in individuals with normal kidney function, unlike previous studies that examined stage 3–5 nephropathy. The authors longitudinally followed low-risk hypertensive subjects with normal kidney function for a median of 5.8 years and concluded that baseline pulse pressure was predictive of increased rates of decline in the glomerular filtration rate. These data are in agreement with most of the previous studies that examined patients with advanced kidney disease. This was, however, a much younger group of subjects, namely 48 years of age compared with patients in the advanced nephropathy trials who were a decade or more older. In addition, there was a very low incidence of microalbuminuria and an absence of proteinuria in that study, factors associated with abnormal vascular compliance [14]. The use of pulse pressure for stratifying patients to assess a higher risk of declines in kidney function is appealing; however, given the size of the study and the interventions used one must be cautious in tacitly accepting this interpretation. Antihypertensive agents that block the renin–angiotensin–aldosterone system are well known to narrow pulse pressure [15,16]; approximately two-thirds of the subjects studied were receiving angiotensin-converting enzyme inhibitors. Given current knowledge about the treatment of kidney disease, it would be very difficult to assess whether pulse pressure is a predictor of faster declines in kidney function unless a cohort was large enough to account for changes in renin–angiotensin–aldosterone system blockade and patients were recruited with similar underlying disease etiology. Nevertheless, validated risk identifiers of kidney disease progression are valuable as the prevalence of chronic kidney disease and its burden on health costs continues to grow internationally. The prevalence of end-stage renal disease in the US population has been predicted to increase by 48% during the next decade. In the NHANES 1999–2000 survey more than two-thirds of the participants had either stage 3 or 4 nephropathy [17,18]. Whereas the bulk of the data support the use of pulse pressure as an early predictor of kidney disease progression, it is unclear whether it is better than systolic pressure alone. Larger studies are necessary in a cohort with a known and stable natural history of kidney disease to solidify BPP further as a risk marker.
No takes yet. Share an insight, caveat, or question.
Chugh et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: